Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.73 |
| ▸ | GPR183 | P32249 | 2/20 | 0.54 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28629549 | 1.00 | APP (0.73) | APPGPR183VCPNFE2L2CES2 | |
| SCHEMBL10069794 | 0.92 | APP (0.84) | APPVCPCES2CES1 | |
| SCHEMBL30114875 | 0.87 | APP (0.75) | APPGPR183VCPCES2CES1 | |
| SCHEMBL27167232 | 0.86 | APP (0.75) | APPVCPCES2CES1 | |
| SCHEMBL28695966 | 0.86 | APP (0.75) | APPVCPCES2CES1 | |
| SCHEMBL28972824 | 0.84 | APP (0.73) | APPGPR183VCPCES2CES1 | |
| SCHEMBL28972914 | 0.84 | APP (0.73) | APPVCPCES2CES1 | |
| SCHEMBL10069797 | 0.84 | APP (0.72) | APPVCPCES2CES1 | |
| SCHEMBL10069798 | 0.84 | APP (0.72) | APPVCPCES2CES1 | |
| SCHEMBL28972867 | 0.84 | APP (0.68) | APPGPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| EP-2655367-B1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2016-07-06 | — | — | EP | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| WO-2012084711-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MSD OSS B.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | ESR2, ESR1, GPER1 | APP 2073/4885GPR183 706/4885VCP 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.